Dublin – July 5, 2019 – Cosmo Pharmaceuticals N.V. (SIX: COPN), a specialty pharmaceutical company leader in the field of selected gastrointestinal disorders and endoscopy, disclosed today that it has posted on its website a video demonstration of its Artificial Intelligence (AI) device, GI Genius, which was presented during Image 2019, one of the most prestigious endoscopy conferences. The video was not previously available except to attendees of the conference, which took place from June 13-15, at the Humanitas Hospital in Milano Italy.
GI Genius is a new AI-enhanced endoscopy device, providing endoscopists with a virtual second observer to assist in endoscopy exams. Studies have shown that having a second observer can increase polyp detection rate (1,2,3,4). GI Genius utilizes AI deep learning to assist endoscopists in detecting polyps. Cosmo’s partner Medtronic holds worldwide rights to market GI Genius. GI Genius is CE-marked and is now available in Europe; Cosmo is undertaking a U.S. pivotal clinical performance trial to support the device registration with the US Federal Food and Drug Administration (FDA).
Colonoscopies performed with GI Genius were, for the first time, demonstrated live during Image 2019 by prof. Michael Wallace, Gastroenterologist at Mayo Clinic Jacksonville, Florida, prof. Alessandro Repici, Head of Gastroenterology at Humanitas Hospital in Rozzano (Milan) and prof. Cesare Hassan, Gastroenterologist at Hospital Regina Margherita (Rome). These colonoscopies were broadcast during the event to a wide global audience of endoscopy professionals attending the event. A recording of one video was later shared on a social network and has since received over 225,000 views.
“We are thankful for the interest the endoscopy community has shown in GI Genius,” said Alessandro Della Chà, CEO of Cosmo Pharmaceuticals. “In order to make this material more accessible to interested parties, we are making it publicly available on our website for the first time.”
The video recording of the live colonoscopy performed by Prof. Michael Wallace with the assistance of GI Genius has been posted on Cosmo’s website.
Please find the video on Cosmo’s multimedia gallery:
https://www.cosmopharma.com/news-and-media/multimedia-gallery
Watch the video also on youtube:
https://www.youtube.com/watch?v=wXAtyXdaml0&t=16s
__________________________________________________________________________
1 Lee et al., Gastrointest Endosc. 2011 Nov; 74(5):1094-102.
2 Aslanian et al., Am J Gastroenterol. 2013 Feb; 108(2):166-72.
3 Rogart et al., Am J Gastroenterol. 2008 Nov; 103(11):2841-6.
4 Buchner et al., Gastrointest Endosc. 2011 Jun; 73(6):1223-31.
About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused in treating selected Gastrointestinal Disorders and Endoscopy. The Company’s proprietary clinical development pipeline specifically addresses innovative treatments for IBD, Colonic Infections and detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of its novel Artificial Intelligence device to be used in coloscopies and GI procedures. Further, Cosmo is the licensee for US of the novel agent for procedural sedation, Remimazolam. For additional information on Cosmo and its products please visit the Company’s website: www.cosmopharma.com
Next events
Half-Year Results August 2, 2019
Contact
John Manieri, Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 (1) 8170 370
jmanieri@cosmopharma.com
Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.
This communication is not an offer of securities of any issuer. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirement of the US Securities Act of 1933.
This press release constitutes neither an offer to sell nor a solicitation to buy securities and it does not constitute a prospectus within the meaning of article 652a and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange or any similar document. The offer will be made solely by means of, and on the basis of, a securities prospectus to be published. An investment decision regarding the securities to be publicly offered should only be made on the basis of the securities prospectus.
This press release is made to and directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. Any person who is not a relevant person should not act or rely on this press release or any of its contents.
This press release does not constitute an “offer of securities to the public” within the meaning of Directive 2003/71/EC of the European Union (the “Prospectus Directive”) of the securities referred to in it (the “Securities”) in any member state of the European Economic Area (the “EEA”). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.